EUVIMEDEUVIMED entdecken
Übersichtsarbeit

B7x in cancer immunity and immunotherapy

Keywan Mortezaee

International Immunopharmacology · 2023-05 · 118 · 110133

DOI: 10.1016/j.intimp.2023.110133 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-05. Verfasst von Keywan Mortezaee. Beteiligte Einrichtung: Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address: mortezaee.k@muk.ac.ir. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: University of Kurdistan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B7x (also called B7-H4) is a co-inhibitory molecule of B7 family that is highly expressed in non-inflamed or cold cancers, and its aberrant expression is contributed to cancer progression and poor outcomes. B7x preferentially expresses on antigen-presenting cells (APCs) and in tumor cells, and it acts as an alternative anti-inflammatory immune checkpoint for hampering peripheral immune responses. Augmented infiltration of immunosuppressive cells, reduced proliferation and effector function of CD4+ and CD8+ T cells, and increased generation of regulatory T cells (Tregs) are outcomes of increased B7x activity in cancer. Evaluation of B7x in sera can be exploited as an effective biomarker of response in cancer patients. B7x overexpression generally occurs in programmed death-ligand 1 (PD-L1)- cancers and is involved in tumor resistance to anti-programmed death-1 (PD-1), anti-PD-L1 or anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) therapy. Co-expression of B7x receptor with PD-1 on CD8+ T cells has made the anti-B7x a fruitful approach for reinvigoration of the functionality of exhausted T cells and is served as a complementary regimen in patients who are irresponsive to the common immune checkpoint inhibitor (ICI) therapy. An advance in the field is the development of bispecific antibodies against B7x with other regulatory molecules within tumor microenvironment (TME).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesNeoplasmsHumansProgrammed Cell Death 1 ReceptorImmunotherapyT-Lymphocytes, RegulatoryB7-H1 AntigenTumor Microenvironment

Stichwörter der Autor:innen

B7xCD8(+) T cellCancerImmune checkpoint inhibitor (ICI)Programmed death-ligand 1 (PD-L1)

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address: mortezaee.k@muk.ac.ir.

Förderung

  • University of Kurdistan

Zitieren

APA

Mortezaee, K. (2023). B7x in cancer immunity and immunotherapy. International Immunopharmacology, 118, 110133. https://doi.org/10.1016/j.intimp.2023.110133

Vancouver

Mortezaee K. B7x in cancer immunity and immunotherapy. International Immunopharmacology. 2023;118:110133. doi:10.1016/j.intimp.2023.110133

BibTeX
@article{Mortezaee2023,
  author = {Mortezaee, Keywan},
  title = {B7x in cancer immunity and immunotherapy},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {118},
  pages = {110133},
  doi = {10.1016/j.intimp.2023.110133}
}
Kostenlos starten →